PMID- 36031782
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20221207
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 63
IP  - 9
DP  - 2022 Sep
TI  - Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean 
      Patients with Type 2 Diabetes in Real-World Clinical Practice.
PG  - 825-833
LID - 10.3349/ymj.2022.63.9.825 [doi]
AB  - PURPOSE: This study aimed to evaluate the efficacy and tolerability of 
      dapagliflozin as an add-on or a switch therapy to lobeglitazone plus metformin 
      (MFM) in Korean patients with inadequately controlled type 2 diabetes mellitus 
      (T2DM) in real-world clinical practice. MATERIALS AND METHODS: The study included 
      109 patients who started dapagliflozin as add-on or switch therapy to 
      lobeglitazone plus MFM. The primary outcome was a change in glycated hemoglobin 
      (HbA1c) level from baseline after 12 months of treatment. Secondary outcomes 
      included changes in fasting plasma glucose (FPG), lipid profiles, body weight, 
      visceral fat area (VFA), and blood pressure after 12 months of treatment. 
      RESULTS: The baseline HbA1c was 8.3+/-1.3% (8.7+/-1.5% in the add-on group and 
      8.1+/-1.0% in the switch group). After 12 months, mean HbA1c decreased (-0.91%) in 
      all patients (p<0.05) (-1.39% in the add-on group and -0.63% in the switch 
      group). Significant reductions in FPG were also observed in both the add-on and 
      switch groups (-54.37 mg/dL and -24.68 mg/dL, respectively). Overall, there was a 
      significant improvement in serum triglyceride (-24.74 mg/dL), low density 
      lipoprotein cholesterol (-7.92 mg/dL), body weight (-2.98 kg), VFA (-9.00 cm(2)), 
      and systolic blood pressure (-8.67 mm Hg). Approximately 35.8% of patients 
      achieved HbA1c <7.0% after 12 months. CONCLUSION: Dapagliflozin, as an add-on or 
      a switch therapy to lobeglitazone plus MFM, can be a suitable alternative for 
      Korean patients with inadequately controlled T2DM. The combination therapy 
      resulted in significant reductions in HbA1c levels, body weight, and blood 
      pressure.
CI  - (c) Copyright: Yonsei University College of Medicine 2022.
FAU - Seo, Da Hea
AU  - Seo DH
AUID- ORCID: 0000-0003-2767-0293
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Suh, Young Ju
AU  - Suh YJ
AUID- ORCID: 0000-0002-6816-8067
AD  - Department of Biomedical Sciences, Inha University College of Medicine, Incheon, 
      Korea.
FAU - Cho, Yongin
AU  - Cho Y
AUID- ORCID: 0000-0002-4645-816X
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Ahn, Seong Hee
AU  - Ahn SH
AUID- ORCID: 0000-0003-2558-2118
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Seo, Seongha
AU  - Seo S
AUID- ORCID: 0000-0001-6900-4251
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Hong, Seongbin
AU  - Hong S
AUID- ORCID: 0000-0002-8189-395X
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea.
FAU - Lee, Yong-Ho
AU  - Lee YH
AUID- ORCID: 0000-0002-6219-4942
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Korea.
FAU - Choi, Young Ju
AU  - Choi YJ
AUID- ORCID: 0000-0003-0868-1472
AD  - Huh's Diabetes Center, Seoul, Korea.
FAU - Lee, Eunjig
AU  - Lee E
AUID- ORCID: 0000-0002-9876-8370
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
      University College of Medicine, Seoul, Korea.
FAU - Kim, So Hun
AU  - Kim SH
AUID- ORCID: 0000-0002-2554-3664
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha 
      University College of Medicine, Incheon, Korea. shoney@inha.ac.kr.
LA  - eng
GR  - Inha University/Korea
GR  - Chong Kun Dang Pharmaceutical Corp./Korea
PT  - Journal Article
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pyrimidines)
RN  - 0 (Thiazolidinediones)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 9100L32L2N (Metformin)
RN  - MY89F08K5D (lobeglitazone)
SB  - IM
MH  - Benzhydryl Compounds
MH  - Blood Glucose
MH  - Body Weight
MH  - *Diabetes Mellitus, Type 2
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Glucosides
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents
MH  - *Metformin
MH  - Pyrimidines
MH  - Republic of Korea
MH  - Thiazolidinediones
MH  - Treatment Outcome
PMC - PMC9424781
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - sodium-glucose transporter 2 inhibitors
OT  - thiozolidinediones
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2022/08/30 06:00
MHDA- 2022/08/31 06:00
PMCR- 2022/09/01
CRDT- 2022/08/29 02:22
PHST- 2022/03/14 00:00 [received]
PHST- 2022/06/21 00:00 [revised]
PHST- 2022/06/21 00:00 [accepted]
PHST- 2022/08/29 02:22 [entrez]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/09/01 00:00 [pmc-release]
AID - 63.825 [pii]
AID - 10.3349/ymj.2022.63.9.825 [doi]
PST - ppublish
SO  - Yonsei Med J. 2022 Sep;63(9):825-833. doi: 10.3349/ymj.2022.63.9.825.